您当前的位置:
Piceatannol
p56lck/Syk抑制剂,Piceatannol是蛋白质酪氨酸激酶Syk的选择性抑制剂,它能够抑制ICa,L, Ito, IKr,Ca2+转移和除了IK1的Na+-Ca2+交换。
目录号: PC11622 纯度: ≥98%
CAS No. :10083-24-6
商品编号 规格 价格 会员价 是否有货 数量
PC11622-20mg 20mg ¥1038.80 请登录
PC11622-10mM (in 1mL DMSO) 10mM (in 1mL DMSO) ¥715.40 请登录
Medlife所售产品仅用于科学研究(非临床研究),非药品不可食用,不可用于人体或动物的临床诊断和治疗,我们不为个人提供产品及服务。产品COA等资料,可至下方“质量控制”中下载。
中文名称
Piceatannol
中文别名
白皮杉醇;(E)-4-[2-(3,5-二羟基苯)乙烯基]-1,2-苯二酚;3,4,3',5'-四羟基-反式-二苯乙烯;比杉特醇;(E)-3,3',4,5'-四羟基苯乙烯;3'-羟基白藜芦醇;4-[2-(3,5-二羟基苯基)乙烯基]-1,2-苯二酚;Piceatannol 白皮杉醇;白皮杉醇;比杉特醇;比杉特醇;Piceatannol
英文名称
Piceatannol
英文别名
trans-Piceatannol;TRANS-3,3',4,5'-TETRAHYDROXYSTILBENE;PICEATANNOL;(e)-4-[2-(3,5dihydroxyphenyl)ethenyl]1,2-benzenediol;4-[2-(3,5-dihydroxyphenyl)ethenyl]benzene-1,2-diol;(E)-3,3',4,5'-Tetrahydroxystilbene;(E)-Piceatannol;Astringenin;(E)-4-(3,5-Dihydroxystyryl)benzene-1,2-diol;3,3',4,5'-Tetrahydroxy-trans-stilbene;3,3′,4,5′-Stilbenetetrol;3,3′,4,5′-Tetrahydroxy-trans-stilbene;3,4,3',5'-Tetrahydroxy-trans-stilbene;3;3-Hydroxyresveratol;astringinin;piceatanol;3,5,3',4'-Tetrahydroxystilbene;3,3',4'5-Tetrahydroxystilbene;4-[(E)-2-(3,5-dihydroxyphenyl)ethenyl]benzene-1,2-diol;3,3',4,5'-Tetrahydroxystilbene;6KS3LS0D4F;3,3',4,5'-Stilbenetetrol;4-[(E)-2-(3,5-dihydroxyphenyl)vinyl]benzene-1,2-diol;1,2-Benzenediol, 4-(2-(3,5-dihydroxyphenyl)ethenyl)-, (E)-;C14H12O4;NSC365798;MFC
Cas No.
10083-24-6
分子式
C14H12O4
分子量
244.24
包装储存
Powder -20°C 3 years
4°C 2 years
In solvent -80°C 6 months
-20°C 1 month
生物活性

Piceatannol is a well-known Syk inhibitor and reduces the expression of iNOS induced by TNF. Piceatannol is an effective agent for research of acute lung injury (ALI). Piceatannol is a naturally occurring polyphenolic stilbene found in various fruits and vegetables and exhibits anticancer and anti-inflammatory properties. Piceatannol induces apoptosis in DLBCL cell lines. Piceatannol induces autophagy and apoptosis in MOLT-4 human leukemia cells.

性状

Solid

体外研究(In Vitro)

Piceatannol is a resveratrol metabolite.
SYK inhibitor Piceatannol (3.125, 6.25, 12.5, 25, and 50 μM; 72 hours) inhibits cell growth of six diffuse large B cell lymphomas (DLBCL) cell lines (SUDHL-6, U2392,DOHH2,Karpas 422, VAL, OCI Ly19) with IC50s of 18 μM, 25 μM, 37 μM, 48 μM, >50 μM and >50 μM, respectively.

Medlife has not independently confirmed the accuracy of these methods. They are for reference only.

Cell Cytotoxicity Assay

Cell Line: Six DLBCL cell lines (Karpas 422, VAL, SUDHL-6, OCI Ly19, U2392 and DOHH2)
Concentration: 3.125, 6.25, 12.5, 25, and 50 μM
Incubation Time: 72 hours
Result: The IC50s were 18 μM in SUDHL-6, 25 μM in U2392, 37 mM in DOHH2, 48 μM in Karpas 422 and higher than 50 μM in OCI-Ly19 and in VAL.
体内研究(In Vivo)

Piceatannol (10, 20, and 40 mg/kg) inhibits the pulmonary edema and reduces the infiltration of inflammatory cells induced by lipopolysaccharide.
Piceatannol (10, 20, and 40 mg/kg) alleviates the myeloperoxidase activity and inhibits the production of iNOS and COX-2 expressions in lung tissuesinduced by lipopolysaccharide.
Piceatannol (10, 20, and 40 mg/kg; intraperitoneally 1 h) treatment alleviates inflammatory response by inhibiting the activation of TLR/NF-κB signaling pathway in lung tissues during acute lung injury (ALI) induced by LPS.

Medlife has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model: Male C57BL/6 mice (40-50 g)
Dosage: 10, 20, and 40 mg/kg
Administration: Intraperitoneally 1 h before LPS challenge
Result: Significantly reduced the pulmonary edema induced by LPS.
运输条件

Room temperature or refrigerated transportation.

储存方式
Powder -20°C 3 years
4°C 2 years
In solvent -80°C 6 months
-20°C 1 month
结构分类
来源
参考文献
溶解度数据
体外研究: 

DMSO : ≥ 31 mg/mL (126.92 mM)

H2O : 1 mg/mL (4.09 mM; Need ultrasonic)

* "≥" means soluble, but saturation unknown.

配制储备溶液
浓度 溶剂体积 质量 1 mg 5 mg 10 mg
1 mM 4.0943 mL 20.4717 mL 40.9433 mL
5 mM 0.8189 mL 4.0943 mL 8.1887 mL
10 mM 0.4094 mL 2.0472 mL 4.0943 mL
*

产品不同,其溶解度不同。建议根据产品选择合适的溶剂配制储备溶液;配成溶液后,建议分装保存,避免反复冻融造成的产品失效
储备液的保存方式和期限:-80°C, 6 months; -20°C, 1 month。-80°C 储存时,建议在 6 个月内使用,-20°C 储存时,建议在 1 个月内使用。

体内研究:

建议根据您的实验动物和给药方式选择适当的溶解方案。以下溶解方案都建议先按照 体外研究 方式配制澄清的储备液,再依次添加助溶剂:

——为保证实验结果的可靠性,澄清的储备液可以根据储存条件,适当保存;体内实验的工作液,建议您现用现配,当天使用; 以下溶剂前显示的百
分比是指该溶剂在您配制终溶液中的体积占比;如在配制过程中出现沉淀、析出现象,可以通过加热和/或超声的方式助溶

  • 1.

    建议依照次序添加每种溶剂: 10% DMSO    40% PEG300    5% Tween-80    45% saline

    Solubility: ≥ 2.5 mg/mL (10.24 mM); Clear solution

    此方案可获得 ≥ 2.5 mg/mL (10.24 mM,饱和度未知) 的澄清溶液。

    以 1 mL 工作液为例,取 100 μL 25.0 mg/mL 的澄清 DMSO 储备液加到 400 μL PEG300 中,混合均匀;向上述体系中加入50 μL Tween-80,混合均匀;然后继续加入 450 μL生理盐水定容至 1 mL。

    将 0.9 g 氯化钠,完全溶解于 100 mL ddH?O 中,得到澄清透明的生理盐水溶液
  • 2.

    建议依照次序添加每种溶剂: 10% DMSO    90% (20% SBE-β-CD in saline)

    Solubility: ≥ 2.5 mg/mL (10.24 mM); Clear solution

    此方案可获得 ≥ 2.5 mg/mL (10.24 mM,饱和度未知) 的澄清溶液。

    以 1 mL 工作液为例,取 100 μL 25.0 mg/mL 的澄清 DMSO 储备液加到 900 μL 20% 的 SBE-β-CD 生理盐水水溶液中,混合均匀。

    将 2 g 磺丁基醚 β-环糊精加入 5 mL 生理盐水中,再用生理盐水定容至 10 mL,完全溶解,澄清透明
*
搜索质检报告(COA)

1:一般建议:溶解度为Medlife测试数据,可能与文献描述存在差异。这是由于生产工艺和批次不同产生的正常现象。为了使其更好的溶解,请用37℃加热试管并在超声波水浴中震动片刻。不同批次产品溶解度各有差异,仅做参考,具体以实验方案为准。

2:储存条件:粉末-20°C一般情况可以保存3年,溶于溶剂-80°C一般情况可以保存1年。不同产品及不同批次产品可能存在差异,请细致阅读产品信息,并辅助参考相关文献描述。

相关产品

更多
The molarity calculator equation
Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)
The dilution calculator equation
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
This equation is commonly abbreviated as: C1V1 = C2V2